Gilead’s Potential COVID-19 Treatment-Remdesivir Granted FDA Orphan Drug Status
Gilead Sciences's investigational drug remdesivir, on Monday received the orphan drug designation for COVID-19 from the U.S. Food and Drug Administration.
Remdesivir is seen as one of the more promising potential treatments for the coronavirus.
The orphan drug status provides a seven-year market exclusivity period, as well as tax and other incentives for drug companies developing treatments for rare diseases that affect fewer than 200,000 people.
For more information, please see https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=739020